BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10913750)

  • 1. Water-activated, pH-controlled patch in transdermal administration of timolol. II. Drug absorption and skin irritation.
    Sutinen R; Paronen P; Saano V; Urtti A
    Eur J Pharm Sci; 2000 Jul; 11(1):25-31. PubMed ID: 10913750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Water-activated, pH-controlled patch in transdermal administration of timolol. I. Preclinical tests.
    Sutinen R; Paronen P; Urtti A
    Eur J Pharm Sci; 2000 Jul; 11(1):19-24. PubMed ID: 10913749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel transdermal delivery of Timolol maleate using sugar esters: preclinical and clinical studies.
    El-Laithy HM
    Eur J Pharm Biopharm; 2009 May; 72(1):239-45. PubMed ID: 19126429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transdermal timolol: beta blockade and plasma concentrations after application for 48 hours and 7 days.
    McCrea JB; Vlasses PH; Franz TJ; Zeoli L
    Pharmacotherapy; 1990; 10(4):289-93. PubMed ID: 2388875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iontophoretic enhancement of timolol across human dermatomed skin in vitro.
    Fatouros DG; Bouwstra JA
    J Drug Target; 2004 Jan; 12(1):19-24. PubMed ID: 15203908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal delivery of timolol by electroporation through human skin.
    Denet AR; Préat V
    J Control Release; 2003 Mar; 88(2):253-62. PubMed ID: 12628332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Evaluation of Transdermal Patches of Timolol Maleate.
    Panchayya Hiremath SS; Reddy JJ; Jamakandi VG
    Curr Drug Deliv; 2018; 15(5):658-663. PubMed ID: 28969565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iontophoretic in vivo transdermal delivery of beta-blockers in hairless rats and reduced skin irritation by liposomal formulation.
    Conjeevaram R; Chaturvedula A; Betageri GV; Sunkara G; Banga AK
    Pharm Res; 2003 Sep; 20(9):1496-501. PubMed ID: 14567646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and beta-blocking effects of transdermal timolol.
    Kubota K; Yamada T; Kikuchi K; Koyama E; Ishizaki T
    Eur J Clin Pharmacol; 1993; 44(5):493-5. PubMed ID: 8359190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial evaluation of transdermal timolol: serum concentrations and beta-blockade.
    Vlasses PH; Ribeiro LG; Rotmensch HH; Bondi JV; Loper AE; Hichens M; Dunlay MC; Ferguson RK
    J Cardiovasc Pharmacol; 1985; 7(2):245-50. PubMed ID: 2581075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Skin irritation induced by topically applied timolol.
    Kubota K; Koyama E; Yasuda K
    Br J Clin Pharmacol; 1991 Apr; 31(4):471-5. PubMed ID: 2049257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between amount of beta-blockers permeating through the stratum corneum and skin irritation after application of beta-blocker adhesive patches to guinea pig skin.
    Kobayashi I; Hosaka K; Ueno T; Maruo H; Kamiyama M; Konno C; Gemba M
    Biol Pharm Bull; 1997 Apr; 20(4):421-7. PubMed ID: 9145222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-dimensional transport analysis of transdermal drug absorption with a non-perfect sink boundary condition at the skin-capillary interface.
    Simon L; Ospina J
    Math Biosci; 2013 Jul; 244(1):58-67. PubMed ID: 23624255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A random walk method for percutaneous drug absorption pharmacokinetics: application to repeated administration of a therapeutic timolol patch.
    Kubota K; Koyama E; Yasuda K
    J Pharm Sci; 1991 Aug; 80(8):752-6. PubMed ID: 1791535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Transdermal properties of timolol and factors affecting its permeability in vitro].
    Xu YZ; Xu HN
    Yao Xue Xue Bao; 1992; 27(6):467-71. PubMed ID: 1442076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The bioavailability of transdermal therapeutic system of timolol].
    Ji XF; Ping QN; Liu GJ; Yu ST
    Yao Xue Xue Bao; 1993; 28(8):609-13. PubMed ID: 8285070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between the iontophoretic and passive transdermal delivery of timolol maleate across human cadaver skin.
    Soni S; Dixit VK
    Pharmazie; 1994 Jan; 49(1):73-4. PubMed ID: 8140139
    [No Abstract]   [Full Text] [Related]  

  • 18. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and pharmacokinetic evaluations.
    Mutalik S; Udupa N
    J Pharm Sci; 2004 Jun; 93(6):1577-94. PubMed ID: 15124215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of the bioavailability of an antihypertensive drug by transdermal protransfersomal system: formulation and in vivo study.
    Morsi NM; Aboelwafa AA; Dawoud MHS
    J Liposome Res; 2018 Jun; 28(2):137-148. PubMed ID: 28264602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamic effects of transdermal bupranolol and timolol in vivo: comparison of microemulsions and matrix patches as vehicle.
    Kemken J; Ziegler A; Müller BW
    Methods Find Exp Clin Pharmacol; 1991 Jun; 13(5):361-5. PubMed ID: 1921573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.